DORYX (doxycycline hyclate) by Pfizer is tetracycline-class antimicrobial drug [ see ]. First approved in 1985.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
DORYX is a delayed-release oral capsule formulation of doxycycline hyclate, a tetracycline-class antimicrobial. It is used to treat bacterial infections across multiple indications. The drug works by inhibiting bacterial protein synthesis, making it bacteriostatic.
As LOE approaches, the brand team is likely in defensive mode with reduced headcount expectations and focus shifting toward cost management and generic transition planning.
tetracycline-class antimicrobial drug [ see ].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate
Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
DORYX offers limited career advancement due to its LOE-approaching lifecycle and minimal linked job openings. Professionals joining this product should expect defensive portfolio strategies and potential team restructuring as generic competition intensifies.
Worked on DORYX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo